SlideShare a Scribd company logo
1 of 13
Download to read offline
Editorial Slides
VP Watch, April 24, 2002, Volume 2, Issue 16
CRP; A Risk Factor Not a Risk Marker?
•
• CRP is an acute-phase reactant that serves as a
pattern-recognition molecule in the innate immune
system.
• Ridker et al analyzed data from the Physician’s Health
Study and demonstrated that circulating CRP levels
provided significant incremental prognostic information
over and above total cholesterol to HDL ratio. 4
• CRP levels have been considered to reflect the extent of
inflammatory reactions in the atherosclerotic vessels.
5,6
• Also measures of body fat are strongly associated with
circulating levels of CRP and fibrinogen. 7
 High-sensitivity CRP (HSCRP) is a strong independent predictor of
endothelial dysfunction, future myocardial dysfunction, stroke, peripheral
artery disease, and vascular death among individuals without known
cardiovascular disease. 10,11
 Ridker et al. in cohort of women measured levels of homocysteine,
lipoprotein(a), several inflammatory parameters including HSCRP, and a
full lipid panel as markers of subsequent vascular risk. 12
 They showed that HSCRP was the single strongest predictor of risk. In
multivariate analysis, only HSCRP level and total / HDL ratio proved to
have independent predictive value once age, smoking status, obesity,
hypertension, family history, and diabetes also were accounted for.
 Yeh and colleagues found that CRP can induce
adhesion molecule expression by human endothelial
cells. 3
 They showed that CRP, at concentrations 5 µg/mL,
has significant pro-inflammatory effects in both umbilical
vein and coronary artery endothelial cells, inducing high
levels of expression of ICAM-1, VCAM-1, and
E-selectin. 3
 Lemieux and colleagues showed significant
relationships between plasma CRP and measures of
adiposity and of insulin resistance but no association
with the plasma lipoprotein-lipid profile in healthy
asymptomatic men. 8
 Therefore, these results suggest that abdominal
obesity is the critical correlate of elevated CRP
concentrations found in men with atherogenic
dyslipidemia of the insulin resistance syndrome.
 Yudkin et al. have shown that an increased plasma
CRP concentration was related to the features of
insulin resistance syndrome and to endothelial
dysfunction. 9
 As reported in this week of VP Watch,
Verma and colleagues showed that incubation
of human venous endothelial cells with
recombinant human CRP resulted in a marked
increase in ICAM-1 and VCAM-1 expression.
 They found that incubation of human
endothelial cells with recombinant CRP resulted
in a marked increase in ICAM-1 and VCAM-1
expression and also increasing monocyte
chemoattractant chemokine-1 production.13
CRP Induces ET-1 and IL-6 Production
CRP
0
50
100
150
200
Control CRP+Bosentan
IL-6
Effects of human recombinant CRP (25
µg/mL, 24 hours) on IL-6 production in human
saphenous vein endothelial cells (2nd
through 5th passage) in the presence and
absence of bosentan (10 µmol/L).
0.0
2.0
4.0
6.0
8.0
10.0
12.0
Control CRP CRP+IL-
6Ab
ET-1
Effects of human recombinant CRP (25
µg/mL, 24 hours) on ET-1 production in
human saphenous vein endothelial cells (2nd
through 5th passage) in the presence and
absence of anti–IL-6 antibody (5 µmol/L).
Endothelin Antagonism and Interleukin-6 Inhibition Attenuate the Proatherogenic Effects of C-Reactive Protein; Subodh Verma,
Shu-Hong Li, Mitesh V. Badiwala, Richard D. Weisel, Paul W.M. Fedak, Ren-Ke Li, Bikramjit Dhillon, and Donald A.G. Mickle
Effect of Human Recombinant CRP on LDL
Uptake in Human Macrophages
LDL
LDL+CRP
LDL+CRP+Bosentan
LDL+CRP+IL-6Ab
0.0
10.0
20.0
30.0
40.0
50.0
60.0
70.0
80.0
90.0
LDL LDL+CRP+IL-6Ab
CD14
+CD3
2
Positi
ve
Cells
The effects of CRP on LDL uptake were assessed in macrophages
using immunofluorescent labeling of CD32 and CD14.
Endothelin Antagonism and Interleukin-6 Inhibition Attenuate the Proatherogenic Effects of C-Reactive Protein; Subodh Verma,
Shu-Hong Li, Mitesh V. Badiwala, Richard D. Weisel, Paul W.M. Fedak, Ren-Ke Li, Bikramjit Dhillon, and Donald A.G. Mickle
• Verma and colleagues showed that
both bosentan (endothelin antagonism)
and anti–IL-6 antibodies attenuated
CRP-mediated expression of adhesion
molecules, MCP-1 secretion, and
macrophage LDL uptake. 13
Conclusion
 CRP directly facilitates endothelial cell adhesion
molecule expression, MCP-1 production, and
macrophage LDL uptake.
 CRP may not be only a marker rather an active players
in atherosclerosis.
 CRP may be the link between obesity (insulin
resistance) and atherosclerosis.
Questions:
• Now that we hear CRP is more than a
marker, the question is whether this role of
CRP specifically pertains to macrophages
in atherosclerosis or CRP plays similar
inflammatory role in other chronic
inflammatory diseases such as
rheumatoid arthritis?
Questions:
• If CRP is indeed a risk factor, should we try to
lower CRP? In other words, do we need to
launch CRP lowering trial? (like lipid lowering
trial)
• Can we create an animal model in which
increasing CRP increases plaque inflammation?
• Knowing the independent risk value of CRP,
should it be included in Framingham Risk
Score?
1) Libby P, Geng YJ, Sukhova GK, et al. Molecular determinants of atherosclerotic plaque vulnerability. Ann N Y
Acad Sci. 1997;811:134–145.
2) Pasceri V, Yeh ET. A tale of two diseases: atherosclerosis and rheumatoid arthritis. Circulation.
1999;100:2124–2126
3) Pasceri, V., Willerson, J. T., Yeh, E. T. H. (2000). Direct Proinflammatory Effect of C-Reactive Protein on
Human Endothelial Cells. Circulation 102: 2165-2168
4) Ridker PM, Glynn RJ, Hennekens CH. C-reactive protein adds to the predictive value of total and HDL
cholesterol in determining risk of first myocardial infarction. Circulation. 1998;97:2007–2011
5) Heinrich J, Schulte H, Schönfeld R, Köhler E, Assmann G. Association of variables of coagulation, fibrinolysis
and acute-phase with atherosclerosis in coronary and peripheral arteries and those arteries supplying the
brain. Thromb Haemost. 1995;73:374–378
6) Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Plasma concentrations of C-reactive
protein and risk of developing peripheral vascular disease. Circulation. 1998;97:425–428
7) Festa A, D'Agostino R Jr, Williams K, Karter AJ, Mayer-Davis EJ, Tracy RP, Haffner SM.
The relation of body fat mass and distribution to markers of chronic inflammation.
Int J Obes Relat Metab Disord. 2001 Oct;25(10):1407-15
8) Lemieux I, Pascot A, Prud'homme D, Almeras N, Bogaty P, Nadeau A, Bergeron J, Despres JP.
Elevated C-reactive protein: another component of the atherothrombotic profile of abdominal
obesity.Arterioscler Thromb Vasc Biol. 2001 Jun;21(6):961-7
9) Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW. C-reactive protein in healthy subjects: associations with
obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose
tissue? Arterioscler Thromb Vasc Biol. 1999;19:972–978
10) Ridker PM. Novel risk factors and markers for coronary disease. Adv Intern Med. 2000; 45: 391–418
11) Rifai N, Tracy RP, Ridker PM. Clinical efficacy of an automated high-sensitivity C-reactive protein assay. Clin
Chem. 1999; 45: 2136–2141
12) Ridker PM, Hennekens CH, Buring JE, et al. C reactive protein and other markers of inflammation in the
prediction of cardiovascular disease in women. N Engl J Med. 2000;342:836–843
13) Endothelin Antagonism and Interleukin-6 Inhibition Attenuate the Proatherogenic Effects of C-Reactive
Protein; Subodh Verma, Shu-Hong Li, Mitesh V. Badiwala, Richard D. Weisel, Paul W.M. Fedak, Ren-Ke Li,
Bikramjit Dhillon, and Donald A.G. Mickle
References

More Related Content

What's hot

Lee, Jonathan SVS Presentation 2
Lee, Jonathan SVS Presentation 2Lee, Jonathan SVS Presentation 2
Lee, Jonathan SVS Presentation 2Jonathan Lee
 
Omega-3 Polyunsaturated Fatty Acids and Metabolic Syndrome
Omega-3 Polyunsaturated Fatty Acids and Metabolic SyndromeOmega-3 Polyunsaturated Fatty Acids and Metabolic Syndrome
Omega-3 Polyunsaturated Fatty Acids and Metabolic SyndromeJosh Nooner
 
Mixing it up with Myxomatous Degeneration
Mixing it up with Myxomatous DegenerationMixing it up with Myxomatous Degeneration
Mixing it up with Myxomatous DegenerationAmanda Furda
 
2014 cholesterol metabolism and immunity clinical implications
2014 cholesterol metabolism and immunity  clinical implications2014 cholesterol metabolism and immunity  clinical implications
2014 cholesterol metabolism and immunity clinical implicationsclaudia denisse marin rangel
 
Premature Vascular Disease in Autoimmunity
Premature Vascular Disease in AutoimmunityPremature Vascular Disease in Autoimmunity
Premature Vascular Disease in AutoimmunityInsideScientific
 
Towards Digitally Enabled Genomic Medicine: with a Personal Illustration of C...
Towards Digitally Enabled Genomic Medicine: with a Personal Illustration of C...Towards Digitally Enabled Genomic Medicine: with a Personal Illustration of C...
Towards Digitally Enabled Genomic Medicine: with a Personal Illustration of C...Larry Smarr
 
Association of cardio metabolic risk factors, serum nitric oxide metabolite a...
Association of cardio metabolic risk factors, serum nitric oxide metabolite a...Association of cardio metabolic risk factors, serum nitric oxide metabolite a...
Association of cardio metabolic risk factors, serum nitric oxide metabolite a...iosrjce
 
Brianna Betton poster 071816- Final
Brianna Betton poster 071816- FinalBrianna Betton poster 071816- Final
Brianna Betton poster 071816- FinalBrianna Betton
 
Cancer as a metabolic disease 2
Cancer as a metabolic disease 2Cancer as a metabolic disease 2
Cancer as a metabolic disease 2fathi neana
 
Transcriptional signaling pathways inversely regulated in alzheimer's disease...
Transcriptional signaling pathways inversely regulated in alzheimer's disease...Transcriptional signaling pathways inversely regulated in alzheimer's disease...
Transcriptional signaling pathways inversely regulated in alzheimer's disease...Elsa von Licy
 
Bma statins and transplantation
Bma statins and transplantationBma statins and transplantation
Bma statins and transplantationNabil Zeidan
 
Alterations of Mitochondrial Functions and DNA in Diabetic Cardiomyopathy of ...
Alterations of Mitochondrial Functions and DNA in Diabetic Cardiomyopathy of ...Alterations of Mitochondrial Functions and DNA in Diabetic Cardiomyopathy of ...
Alterations of Mitochondrial Functions and DNA in Diabetic Cardiomyopathy of ...CrimsonPublishersIOD
 
Cardiac Inflammation and Repair Following Myocardial Infarction
Cardiac Inflammation and Repair Following Myocardial InfarctionCardiac Inflammation and Repair Following Myocardial Infarction
Cardiac Inflammation and Repair Following Myocardial InfarctionInsideScientific
 
Poster13 laura Abell
Poster13 laura AbellPoster13 laura Abell
Poster13 laura AbellLaura Abell
 
Nutritional immunology, with Professor Philip Calder
Nutritional immunology, with Professor Philip CalderNutritional immunology, with Professor Philip Calder
Nutritional immunology, with Professor Philip CalderIgennus Healthcare Nutrition
 

What's hot (18)

Lee, Jonathan SVS Presentation 2
Lee, Jonathan SVS Presentation 2Lee, Jonathan SVS Presentation 2
Lee, Jonathan SVS Presentation 2
 
Omega-3 Polyunsaturated Fatty Acids and Metabolic Syndrome
Omega-3 Polyunsaturated Fatty Acids and Metabolic SyndromeOmega-3 Polyunsaturated Fatty Acids and Metabolic Syndrome
Omega-3 Polyunsaturated Fatty Acids and Metabolic Syndrome
 
Mixing it up with Myxomatous Degeneration
Mixing it up with Myxomatous DegenerationMixing it up with Myxomatous Degeneration
Mixing it up with Myxomatous Degeneration
 
2014 cholesterol metabolism and immunity clinical implications
2014 cholesterol metabolism and immunity  clinical implications2014 cholesterol metabolism and immunity  clinical implications
2014 cholesterol metabolism and immunity clinical implications
 
Premature Vascular Disease in Autoimmunity
Premature Vascular Disease in AutoimmunityPremature Vascular Disease in Autoimmunity
Premature Vascular Disease in Autoimmunity
 
Towards Digitally Enabled Genomic Medicine: with a Personal Illustration of C...
Towards Digitally Enabled Genomic Medicine: with a Personal Illustration of C...Towards Digitally Enabled Genomic Medicine: with a Personal Illustration of C...
Towards Digitally Enabled Genomic Medicine: with a Personal Illustration of C...
 
Association of cardio metabolic risk factors, serum nitric oxide metabolite a...
Association of cardio metabolic risk factors, serum nitric oxide metabolite a...Association of cardio metabolic risk factors, serum nitric oxide metabolite a...
Association of cardio metabolic risk factors, serum nitric oxide metabolite a...
 
Brianna Betton poster 071816- Final
Brianna Betton poster 071816- FinalBrianna Betton poster 071816- Final
Brianna Betton poster 071816- Final
 
Diabetes and sex hormones
Diabetes and sex hormonesDiabetes and sex hormones
Diabetes and sex hormones
 
Cancer as a metabolic disease 2
Cancer as a metabolic disease 2Cancer as a metabolic disease 2
Cancer as a metabolic disease 2
 
Transcriptional signaling pathways inversely regulated in alzheimer's disease...
Transcriptional signaling pathways inversely regulated in alzheimer's disease...Transcriptional signaling pathways inversely regulated in alzheimer's disease...
Transcriptional signaling pathways inversely regulated in alzheimer's disease...
 
Bma statins and transplantation
Bma statins and transplantationBma statins and transplantation
Bma statins and transplantation
 
Alterations of Mitochondrial Functions and DNA in Diabetic Cardiomyopathy of ...
Alterations of Mitochondrial Functions and DNA in Diabetic Cardiomyopathy of ...Alterations of Mitochondrial Functions and DNA in Diabetic Cardiomyopathy of ...
Alterations of Mitochondrial Functions and DNA in Diabetic Cardiomyopathy of ...
 
Cardiac Inflammation and Repair Following Myocardial Infarction
Cardiac Inflammation and Repair Following Myocardial InfarctionCardiac Inflammation and Repair Following Myocardial Infarction
Cardiac Inflammation and Repair Following Myocardial Infarction
 
Poster13 laura Abell
Poster13 laura AbellPoster13 laura Abell
Poster13 laura Abell
 
Nutritional immunology, with Professor Philip Calder
Nutritional immunology, with Professor Philip CalderNutritional immunology, with Professor Philip Calder
Nutritional immunology, with Professor Philip Calder
 
Poloz_Obesity_CDDis_2015
Poloz_Obesity_CDDis_2015Poloz_Obesity_CDDis_2015
Poloz_Obesity_CDDis_2015
 
Nutritional strategies for cognitive decline
Nutritional strategies for cognitive decline Nutritional strategies for cognitive decline
Nutritional strategies for cognitive decline
 

Viewers also liked

117 mr images of human carotid arteries
117 mr images of human carotid arteries117 mr images of human carotid arteries
117 mr images of human carotid arteriesSHAPE Society
 
209 trans blood vision™
209 trans blood vision™209 trans blood vision™
209 trans blood vision™SHAPE Society
 
199 plaque severity and coronary occlusion
199 plaque severity and coronary occlusion199 plaque severity and coronary occlusion
199 plaque severity and coronary occlusionSHAPE Society
 
190 virus infected monocyes
190 virus infected monocyes190 virus infected monocyes
190 virus infected monocyesSHAPE Society
 
180 aortic thermography catheter
180 aortic thermography catheter180 aortic thermography catheter
180 aortic thermography catheterSHAPE Society
 
159 spio uptake by macrophages
159 spio uptake by macrophages159 spio uptake by macrophages
159 spio uptake by macrophagesSHAPE Society
 
No correlation and low agreement of imaging and inflammatory atherosclerosis’...
No correlation and low agreement of imaging and inflammatory atherosclerosis’...No correlation and low agreement of imaging and inflammatory atherosclerosis’...
No correlation and low agreement of imaging and inflammatory atherosclerosis’...SHAPE Society
 
174 multicontrast mri
174 multicontrast mri174 multicontrast mri
174 multicontrast mriSHAPE Society
 
197 reducing atherosclerosis in mice
197 reducing atherosclerosis in mice197 reducing atherosclerosis in mice
197 reducing atherosclerosis in miceSHAPE Society
 
039 mr contrast agents for vulnerable plaque imaging
039 mr contrast agents for vulnerable plaque imaging039 mr contrast agents for vulnerable plaque imaging
039 mr contrast agents for vulnerable plaque imagingSHAPE Society
 
070 visualization of atherosclerotic vulnerable plaque
070 visualization of atherosclerotic vulnerable plaque070 visualization of atherosclerotic vulnerable plaque
070 visualization of atherosclerotic vulnerable plaqueSHAPE Society
 
061 a nano mega initiative
061 a nano mega initiative061 a nano mega initiative
061 a nano mega initiativeSHAPE Society
 
101205 shape aha 2005 f
101205 shape aha 2005 f101205 shape aha 2005 f
101205 shape aha 2005 fSHAPE Society
 
169 coronary artery surgery study
169 coronary artery surgery study169 coronary artery surgery study
169 coronary artery surgery studySHAPE Society
 
507 stenosis severity and risk benefit
507 stenosis severity and risk benefit507 stenosis severity and risk benefit
507 stenosis severity and risk benefitSHAPE Society
 
Coronary artery disease among asymptomatic diabetic and non-diabetic patients...
Coronary artery disease among asymptomatic diabetic and non-diabetic patients...Coronary artery disease among asymptomatic diabetic and non-diabetic patients...
Coronary artery disease among asymptomatic diabetic and non-diabetic patients...SHAPE Society
 
Phosphorus levels are associated with subclinical atherosclerosis in the gene...
Phosphorus levels are associated with subclinical atherosclerosis in the gene...Phosphorus levels are associated with subclinical atherosclerosis in the gene...
Phosphorus levels are associated with subclinical atherosclerosis in the gene...SHAPE Society
 

Viewers also liked (20)

Braunwald
BraunwaldBraunwald
Braunwald
 
117 mr images of human carotid arteries
117 mr images of human carotid arteries117 mr images of human carotid arteries
117 mr images of human carotid arteries
 
209 trans blood vision™
209 trans blood vision™209 trans blood vision™
209 trans blood vision™
 
199 plaque severity and coronary occlusion
199 plaque severity and coronary occlusion199 plaque severity and coronary occlusion
199 plaque severity and coronary occlusion
 
190 virus infected monocyes
190 virus infected monocyes190 virus infected monocyes
190 virus infected monocyes
 
180 aortic thermography catheter
180 aortic thermography catheter180 aortic thermography catheter
180 aortic thermography catheter
 
159 spio uptake by macrophages
159 spio uptake by macrophages159 spio uptake by macrophages
159 spio uptake by macrophages
 
512 low t3 syndrome
512 low t3 syndrome512 low t3 syndrome
512 low t3 syndrome
 
No correlation and low agreement of imaging and inflammatory atherosclerosis’...
No correlation and low agreement of imaging and inflammatory atherosclerosis’...No correlation and low agreement of imaging and inflammatory atherosclerosis’...
No correlation and low agreement of imaging and inflammatory atherosclerosis’...
 
174 multicontrast mri
174 multicontrast mri174 multicontrast mri
174 multicontrast mri
 
197 reducing atherosclerosis in mice
197 reducing atherosclerosis in mice197 reducing atherosclerosis in mice
197 reducing atherosclerosis in mice
 
039 mr contrast agents for vulnerable plaque imaging
039 mr contrast agents for vulnerable plaque imaging039 mr contrast agents for vulnerable plaque imaging
039 mr contrast agents for vulnerable plaque imaging
 
070 visualization of atherosclerotic vulnerable plaque
070 visualization of atherosclerotic vulnerable plaque070 visualization of atherosclerotic vulnerable plaque
070 visualization of atherosclerotic vulnerable plaque
 
061 a nano mega initiative
061 a nano mega initiative061 a nano mega initiative
061 a nano mega initiative
 
101205 shape aha 2005 f
101205 shape aha 2005 f101205 shape aha 2005 f
101205 shape aha 2005 f
 
169 coronary artery surgery study
169 coronary artery surgery study169 coronary artery surgery study
169 coronary artery surgery study
 
507 stenosis severity and risk benefit
507 stenosis severity and risk benefit507 stenosis severity and risk benefit
507 stenosis severity and risk benefit
 
102 hot plaque
102 hot plaque102 hot plaque
102 hot plaque
 
Coronary artery disease among asymptomatic diabetic and non-diabetic patients...
Coronary artery disease among asymptomatic diabetic and non-diabetic patients...Coronary artery disease among asymptomatic diabetic and non-diabetic patients...
Coronary artery disease among asymptomatic diabetic and non-diabetic patients...
 
Phosphorus levels are associated with subclinical atherosclerosis in the gene...
Phosphorus levels are associated with subclinical atherosclerosis in the gene...Phosphorus levels are associated with subclinical atherosclerosis in the gene...
Phosphorus levels are associated with subclinical atherosclerosis in the gene...
 

Similar to 228 crp, is it a risk factor not a risk marker

230 plaque crp or myocardial crp
230 plaque crp or myocardial crp230 plaque crp or myocardial crp
230 plaque crp or myocardial crpSHAPE Society
 
206 crp lowering or crp guided trial
206 crp lowering or crp guided trial206 crp lowering or crp guided trial
206 crp lowering or crp guided trialSHAPE Society
 
Marc Penn, MD, PhD, FACC - Trials and Tribulations of Assessing CVD Risk in ...
Marc Penn,  MD, PhD, FACC - Trials and Tribulations of Assessing CVD Risk in ...Marc Penn,  MD, PhD, FACC - Trials and Tribulations of Assessing CVD Risk in ...
Marc Penn, MD, PhD, FACC - Trials and Tribulations of Assessing CVD Risk in ...Cleveland HeartLab, Inc.
 
224 k ras polymorphism in cancer, for atherosclerosis
224 k ras polymorphism in cancer, for atherosclerosis224 k ras polymorphism in cancer, for atherosclerosis
224 k ras polymorphism in cancer, for atherosclerosisSHAPE Society
 
217 c reactive protein
217 c reactive protein217 c reactive protein
217 c reactive proteinSHAPE Society
 
Evaluation of Serum C‑reactive Protein Levels in Subjects with [Autosaved].pptx
Evaluation of Serum C‑reactive Protein Levels in Subjects with [Autosaved].pptxEvaluation of Serum C‑reactive Protein Levels in Subjects with [Autosaved].pptx
Evaluation of Serum C‑reactive Protein Levels in Subjects with [Autosaved].pptxSrishtyGoyal5
 
259 crp as a risk factor
259 crp as a risk factor259 crp as a risk factor
259 crp as a risk factorSHAPE Society
 
Dr. Maureen McMahon Presents "“Heart Disease and Preventive Measures” at Lupu...
Dr. Maureen McMahon Presents "“Heart Disease and Preventive Measures” at Lupu...Dr. Maureen McMahon Presents "“Heart Disease and Preventive Measures” at Lupu...
Dr. Maureen McMahon Presents "“Heart Disease and Preventive Measures” at Lupu...LupusNY
 
Inflammationandatherosclerosis 191217191540 (2)
Inflammationandatherosclerosis 191217191540 (2)Inflammationandatherosclerosis 191217191540 (2)
Inflammationandatherosclerosis 191217191540 (2)Jonathan Bishinsky, FRCPC
 
Inflammation and atherosclerosis
Inflammation and atherosclerosisInflammation and atherosclerosis
Inflammation and atherosclerosisDIPAK PATADE
 
729c7635497821959491250-Drapkina-Pace17Oct-000271.ppt
729c7635497821959491250-Drapkina-Pace17Oct-000271.ppt729c7635497821959491250-Drapkina-Pace17Oct-000271.ppt
729c7635497821959491250-Drapkina-Pace17Oct-000271.pptASIFGULAM1
 
8 8 16_gerber_savagian_poster_final
8 8 16_gerber_savagian_poster_final8 8 16_gerber_savagian_poster_final
8 8 16_gerber_savagian_poster_finalIvor Cummins
 

Similar to 228 crp, is it a risk factor not a risk marker (20)

230 plaque crp or myocardial crp
230 plaque crp or myocardial crp230 plaque crp or myocardial crp
230 plaque crp or myocardial crp
 
230 plaque crp or myocardial crp
230 plaque crp or myocardial crp230 plaque crp or myocardial crp
230 plaque crp or myocardial crp
 
Es v2n17
Es v2n17Es v2n17
Es v2n17
 
Esv2n26
Esv2n26Esv2n26
Esv2n26
 
206 crp lowering or crp guided trial
206 crp lowering or crp guided trial206 crp lowering or crp guided trial
206 crp lowering or crp guided trial
 
206 crp lowering or crp guided trial
206 crp lowering or crp guided trial206 crp lowering or crp guided trial
206 crp lowering or crp guided trial
 
Marc Penn, MD, PhD, FACC - Trials and Tribulations of Assessing CVD Risk in ...
Marc Penn,  MD, PhD, FACC - Trials and Tribulations of Assessing CVD Risk in ...Marc Penn,  MD, PhD, FACC - Trials and Tribulations of Assessing CVD Risk in ...
Marc Penn, MD, PhD, FACC - Trials and Tribulations of Assessing CVD Risk in ...
 
224 k ras polymorphism in cancer, for atherosclerosis
224 k ras polymorphism in cancer, for atherosclerosis224 k ras polymorphism in cancer, for atherosclerosis
224 k ras polymorphism in cancer, for atherosclerosis
 
224 k ras polymorphism in cancer, for atherosclerosis
224 k ras polymorphism in cancer, for atherosclerosis224 k ras polymorphism in cancer, for atherosclerosis
224 k ras polymorphism in cancer, for atherosclerosis
 
Esv2n21
Esv2n21Esv2n21
Esv2n21
 
217 c reactive protein
217 c reactive protein217 c reactive protein
217 c reactive protein
 
Evaluation of Serum C‑reactive Protein Levels in Subjects with [Autosaved].pptx
Evaluation of Serum C‑reactive Protein Levels in Subjects with [Autosaved].pptxEvaluation of Serum C‑reactive Protein Levels in Subjects with [Autosaved].pptx
Evaluation of Serum C‑reactive Protein Levels in Subjects with [Autosaved].pptx
 
259 crp as a risk factor
259 crp as a risk factor259 crp as a risk factor
259 crp as a risk factor
 
259 crp as a risk factor
259 crp as a risk factor259 crp as a risk factor
259 crp as a risk factor
 
Esv2n47
Esv2n47Esv2n47
Esv2n47
 
Dr. Maureen McMahon Presents "“Heart Disease and Preventive Measures” at Lupu...
Dr. Maureen McMahon Presents "“Heart Disease and Preventive Measures” at Lupu...Dr. Maureen McMahon Presents "“Heart Disease and Preventive Measures” at Lupu...
Dr. Maureen McMahon Presents "“Heart Disease and Preventive Measures” at Lupu...
 
Inflammationandatherosclerosis 191217191540 (2)
Inflammationandatherosclerosis 191217191540 (2)Inflammationandatherosclerosis 191217191540 (2)
Inflammationandatherosclerosis 191217191540 (2)
 
Inflammation and atherosclerosis
Inflammation and atherosclerosisInflammation and atherosclerosis
Inflammation and atherosclerosis
 
729c7635497821959491250-Drapkina-Pace17Oct-000271.ppt
729c7635497821959491250-Drapkina-Pace17Oct-000271.ppt729c7635497821959491250-Drapkina-Pace17Oct-000271.ppt
729c7635497821959491250-Drapkina-Pace17Oct-000271.ppt
 
8 8 16_gerber_savagian_poster_final
8 8 16_gerber_savagian_poster_final8 8 16_gerber_savagian_poster_final
8 8 16_gerber_savagian_poster_final
 

More from SHAPE Society

Acc vp-org 3-02 stone
Acc vp-org 3-02 stoneAcc vp-org 3-02 stone
Acc vp-org 3-02 stoneSHAPE Society
 
Acc presentation macrophage (1)
Acc presentation macrophage (1)Acc presentation macrophage (1)
Acc presentation macrophage (1)SHAPE Society
 
Acc presentation (1)
Acc presentation (1)Acc presentation (1)
Acc presentation (1)SHAPE Society
 
Acc presentation lipid coated(2)
Acc presentation lipid coated(2)Acc presentation lipid coated(2)
Acc presentation lipid coated(2)SHAPE Society
 
Acc 2002 microarray mehran for print
Acc 2002 microarray mehran for printAcc 2002 microarray mehran for print
Acc 2002 microarray mehran for printSHAPE Society
 
Acc 2002 mehran for print
Acc 2002  mehran for printAcc 2002  mehran for print
Acc 2002 mehran for printSHAPE Society
 
Acc2002 thermography
Acc2002 thermographyAcc2002 thermography
Acc2002 thermographySHAPE Society
 
#1 killer of human beings in the 21st century
#1 killer of human beings in the 21st century#1 killer of human beings in the 21st century
#1 killer of human beings in the 21st centurySHAPE Society
 
A20 is an atherosclerosis
A20 is an atherosclerosisA20 is an atherosclerosis
A20 is an atherosclerosisSHAPE Society
 
511 first steps towards understanding
511 first steps towards understanding511 first steps towards understanding
511 first steps towards understandingSHAPE Society
 
1688 azadpour 3 12 02
1688 azadpour 3 12 021688 azadpour 3 12 02
1688 azadpour 3 12 02SHAPE Society
 

More from SHAPE Society (20)

Barth imt
Barth imtBarth imt
Barth imt
 
Acc vp-org 3-02 stone
Acc vp-org 3-02 stoneAcc vp-org 3-02 stone
Acc vp-org 3-02 stone
 
Acc v porg becker
Acc v porg beckerAcc v porg becker
Acc v porg becker
 
Acc 2005-1, v pl-vp
Acc 2005-1, v pl-vpAcc 2005-1, v pl-vp
Acc 2005-1, v pl-vp
 
Acc presentation macrophage (1)
Acc presentation macrophage (1)Acc presentation macrophage (1)
Acc presentation macrophage (1)
 
Acc v porg
Acc v porgAcc v porg
Acc v porg
 
Acc presentation (1)
Acc presentation (1)Acc presentation (1)
Acc presentation (1)
 
Ac cculprit
Ac cculpritAc cculprit
Ac cculprit
 
Acc presentation lipid coated(2)
Acc presentation lipid coated(2)Acc presentation lipid coated(2)
Acc presentation lipid coated(2)
 
Acc 2002 microarray mehran for print
Acc 2002 microarray mehran for printAcc 2002 microarray mehran for print
Acc 2002 microarray mehran for print
 
Acc booth inventory
Acc booth inventoryAcc booth inventory
Acc booth inventory
 
Acc 04 vuln pt
Acc 04 vuln ptAcc 04 vuln pt
Acc 04 vuln pt
 
Acc 2002 mehran for print
Acc 2002  mehran for printAcc 2002  mehran for print
Acc 2002 mehran for print
 
Acc2002 thermography
Acc2002 thermographyAcc2002 thermography
Acc2002 thermography
 
A20 gene
A20 geneA20 gene
A20 gene
 
#1 killer of human beings in the 21st century
#1 killer of human beings in the 21st century#1 killer of human beings in the 21st century
#1 killer of human beings in the 21st century
 
A20 is an atherosclerosis
A20 is an atherosclerosisA20 is an atherosclerosis
A20 is an atherosclerosis
 
103100
103100103100
103100
 
511 first steps towards understanding
511 first steps towards understanding511 first steps towards understanding
511 first steps towards understanding
 
1688 azadpour 3 12 02
1688 azadpour 3 12 021688 azadpour 3 12 02
1688 azadpour 3 12 02
 

Recently uploaded

Good Laboratory Practice (GLP) in Pharma-LikeWays.pptx
Good Laboratory Practice (GLP) in Pharma-LikeWays.pptxGood Laboratory Practice (GLP) in Pharma-LikeWays.pptx
Good Laboratory Practice (GLP) in Pharma-LikeWays.pptxLikeways
 
EXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionEXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionkrishnareddy157915
 
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D.  Bawankar.pptPharmacokinetic Models by Dr. Ram D.  Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D. Bawankar.pptRamDBawankar1
 
Microbiology lecture presentation-1.pptx
Microbiology lecture presentation-1.pptxMicrobiology lecture presentation-1.pptx
Microbiology lecture presentation-1.pptxkitati1
 
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio..."Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio...Sujoy Dasgupta
 
High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)kishan singh tomar
 
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.aarjukhadka22
 
power point presentation of Clinical evaluation of strabismus
power point presentation of Clinical evaluation  of strabismuspower point presentation of Clinical evaluation  of strabismus
power point presentation of Clinical evaluation of strabismusChandrasekar Reddy
 
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfSGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfHongBiThi1
 
Physiotherapy Management of Rheumatoid Arthritis
Physiotherapy Management of Rheumatoid ArthritisPhysiotherapy Management of Rheumatoid Arthritis
Physiotherapy Management of Rheumatoid ArthritisNilofarRasheed1
 
AUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsAUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsMedicoseAcademics
 
QUESTIONS & ANSWERS FOR QUALITY ASSURANCE, RADIATIONBIOLOGY& RADIATION HAZARD...
QUESTIONS & ANSWERS FOR QUALITY ASSURANCE, RADIATIONBIOLOGY& RADIATION HAZARD...QUESTIONS & ANSWERS FOR QUALITY ASSURANCE, RADIATIONBIOLOGY& RADIATION HAZARD...
QUESTIONS & ANSWERS FOR QUALITY ASSURANCE, RADIATIONBIOLOGY& RADIATION HAZARD...Ganesan Yogananthem
 
Moving Forward After Uterine Cancer Treatment: Surveillance Strategies, Testi...
Moving Forward After Uterine Cancer Treatment: Surveillance Strategies, Testi...Moving Forward After Uterine Cancer Treatment: Surveillance Strategies, Testi...
Moving Forward After Uterine Cancer Treatment: Surveillance Strategies, Testi...bkling
 
Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.kishan singh tomar
 
BENIGN BREAST DISEASE
BENIGN BREAST DISEASE BENIGN BREAST DISEASE
BENIGN BREAST DISEASE Mamatha Lakka
 
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfCONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfDolisha Warbi
 
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...Shubhanshu Gaurav
 
Basic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptxBasic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptxkomalt2001
 
How to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyHow to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyZurück zum Ursprung
 
Role of Soap based and synthetic or syndets bar
Role of  Soap based and synthetic or syndets barRole of  Soap based and synthetic or syndets bar
Role of Soap based and synthetic or syndets barmohitRahangdale
 

Recently uploaded (20)

Good Laboratory Practice (GLP) in Pharma-LikeWays.pptx
Good Laboratory Practice (GLP) in Pharma-LikeWays.pptxGood Laboratory Practice (GLP) in Pharma-LikeWays.pptx
Good Laboratory Practice (GLP) in Pharma-LikeWays.pptx
 
EXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionEXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung function
 
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D.  Bawankar.pptPharmacokinetic Models by Dr. Ram D.  Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
 
Microbiology lecture presentation-1.pptx
Microbiology lecture presentation-1.pptxMicrobiology lecture presentation-1.pptx
Microbiology lecture presentation-1.pptx
 
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio..."Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
 
High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)
 
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
 
power point presentation of Clinical evaluation of strabismus
power point presentation of Clinical evaluation  of strabismuspower point presentation of Clinical evaluation  of strabismus
power point presentation of Clinical evaluation of strabismus
 
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfSGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
 
Physiotherapy Management of Rheumatoid Arthritis
Physiotherapy Management of Rheumatoid ArthritisPhysiotherapy Management of Rheumatoid Arthritis
Physiotherapy Management of Rheumatoid Arthritis
 
AUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsAUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functions
 
QUESTIONS & ANSWERS FOR QUALITY ASSURANCE, RADIATIONBIOLOGY& RADIATION HAZARD...
QUESTIONS & ANSWERS FOR QUALITY ASSURANCE, RADIATIONBIOLOGY& RADIATION HAZARD...QUESTIONS & ANSWERS FOR QUALITY ASSURANCE, RADIATIONBIOLOGY& RADIATION HAZARD...
QUESTIONS & ANSWERS FOR QUALITY ASSURANCE, RADIATIONBIOLOGY& RADIATION HAZARD...
 
Moving Forward After Uterine Cancer Treatment: Surveillance Strategies, Testi...
Moving Forward After Uterine Cancer Treatment: Surveillance Strategies, Testi...Moving Forward After Uterine Cancer Treatment: Surveillance Strategies, Testi...
Moving Forward After Uterine Cancer Treatment: Surveillance Strategies, Testi...
 
Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.
 
BENIGN BREAST DISEASE
BENIGN BREAST DISEASE BENIGN BREAST DISEASE
BENIGN BREAST DISEASE
 
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfCONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
 
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
 
Basic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptxBasic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptx
 
How to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyHow to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturally
 
Role of Soap based and synthetic or syndets bar
Role of  Soap based and synthetic or syndets barRole of  Soap based and synthetic or syndets bar
Role of Soap based and synthetic or syndets bar
 

228 crp, is it a risk factor not a risk marker

  • 1. Editorial Slides VP Watch, April 24, 2002, Volume 2, Issue 16 CRP; A Risk Factor Not a Risk Marker?
  • 2. • • CRP is an acute-phase reactant that serves as a pattern-recognition molecule in the innate immune system. • Ridker et al analyzed data from the Physician’s Health Study and demonstrated that circulating CRP levels provided significant incremental prognostic information over and above total cholesterol to HDL ratio. 4 • CRP levels have been considered to reflect the extent of inflammatory reactions in the atherosclerotic vessels. 5,6 • Also measures of body fat are strongly associated with circulating levels of CRP and fibrinogen. 7
  • 3.  High-sensitivity CRP (HSCRP) is a strong independent predictor of endothelial dysfunction, future myocardial dysfunction, stroke, peripheral artery disease, and vascular death among individuals without known cardiovascular disease. 10,11  Ridker et al. in cohort of women measured levels of homocysteine, lipoprotein(a), several inflammatory parameters including HSCRP, and a full lipid panel as markers of subsequent vascular risk. 12  They showed that HSCRP was the single strongest predictor of risk. In multivariate analysis, only HSCRP level and total / HDL ratio proved to have independent predictive value once age, smoking status, obesity, hypertension, family history, and diabetes also were accounted for.
  • 4.  Yeh and colleagues found that CRP can induce adhesion molecule expression by human endothelial cells. 3  They showed that CRP, at concentrations 5 µg/mL, has significant pro-inflammatory effects in both umbilical vein and coronary artery endothelial cells, inducing high levels of expression of ICAM-1, VCAM-1, and E-selectin. 3
  • 5.  Lemieux and colleagues showed significant relationships between plasma CRP and measures of adiposity and of insulin resistance but no association with the plasma lipoprotein-lipid profile in healthy asymptomatic men. 8  Therefore, these results suggest that abdominal obesity is the critical correlate of elevated CRP concentrations found in men with atherogenic dyslipidemia of the insulin resistance syndrome.  Yudkin et al. have shown that an increased plasma CRP concentration was related to the features of insulin resistance syndrome and to endothelial dysfunction. 9
  • 6.  As reported in this week of VP Watch, Verma and colleagues showed that incubation of human venous endothelial cells with recombinant human CRP resulted in a marked increase in ICAM-1 and VCAM-1 expression.  They found that incubation of human endothelial cells with recombinant CRP resulted in a marked increase in ICAM-1 and VCAM-1 expression and also increasing monocyte chemoattractant chemokine-1 production.13
  • 7. CRP Induces ET-1 and IL-6 Production CRP 0 50 100 150 200 Control CRP+Bosentan IL-6 Effects of human recombinant CRP (25 µg/mL, 24 hours) on IL-6 production in human saphenous vein endothelial cells (2nd through 5th passage) in the presence and absence of bosentan (10 µmol/L). 0.0 2.0 4.0 6.0 8.0 10.0 12.0 Control CRP CRP+IL- 6Ab ET-1 Effects of human recombinant CRP (25 µg/mL, 24 hours) on ET-1 production in human saphenous vein endothelial cells (2nd through 5th passage) in the presence and absence of anti–IL-6 antibody (5 µmol/L). Endothelin Antagonism and Interleukin-6 Inhibition Attenuate the Proatherogenic Effects of C-Reactive Protein; Subodh Verma, Shu-Hong Li, Mitesh V. Badiwala, Richard D. Weisel, Paul W.M. Fedak, Ren-Ke Li, Bikramjit Dhillon, and Donald A.G. Mickle
  • 8. Effect of Human Recombinant CRP on LDL Uptake in Human Macrophages LDL LDL+CRP LDL+CRP+Bosentan LDL+CRP+IL-6Ab 0.0 10.0 20.0 30.0 40.0 50.0 60.0 70.0 80.0 90.0 LDL LDL+CRP+IL-6Ab CD14 +CD3 2 Positi ve Cells The effects of CRP on LDL uptake were assessed in macrophages using immunofluorescent labeling of CD32 and CD14. Endothelin Antagonism and Interleukin-6 Inhibition Attenuate the Proatherogenic Effects of C-Reactive Protein; Subodh Verma, Shu-Hong Li, Mitesh V. Badiwala, Richard D. Weisel, Paul W.M. Fedak, Ren-Ke Li, Bikramjit Dhillon, and Donald A.G. Mickle
  • 9. • Verma and colleagues showed that both bosentan (endothelin antagonism) and anti–IL-6 antibodies attenuated CRP-mediated expression of adhesion molecules, MCP-1 secretion, and macrophage LDL uptake. 13
  • 10. Conclusion  CRP directly facilitates endothelial cell adhesion molecule expression, MCP-1 production, and macrophage LDL uptake.  CRP may not be only a marker rather an active players in atherosclerosis.  CRP may be the link between obesity (insulin resistance) and atherosclerosis.
  • 11. Questions: • Now that we hear CRP is more than a marker, the question is whether this role of CRP specifically pertains to macrophages in atherosclerosis or CRP plays similar inflammatory role in other chronic inflammatory diseases such as rheumatoid arthritis?
  • 12. Questions: • If CRP is indeed a risk factor, should we try to lower CRP? In other words, do we need to launch CRP lowering trial? (like lipid lowering trial) • Can we create an animal model in which increasing CRP increases plaque inflammation? • Knowing the independent risk value of CRP, should it be included in Framingham Risk Score?
  • 13. 1) Libby P, Geng YJ, Sukhova GK, et al. Molecular determinants of atherosclerotic plaque vulnerability. Ann N Y Acad Sci. 1997;811:134–145. 2) Pasceri V, Yeh ET. A tale of two diseases: atherosclerosis and rheumatoid arthritis. Circulation. 1999;100:2124–2126 3) Pasceri, V., Willerson, J. T., Yeh, E. T. H. (2000). Direct Proinflammatory Effect of C-Reactive Protein on Human Endothelial Cells. Circulation 102: 2165-2168 4) Ridker PM, Glynn RJ, Hennekens CH. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation. 1998;97:2007–2011 5) Heinrich J, Schulte H, Schönfeld R, Köhler E, Assmann G. Association of variables of coagulation, fibrinolysis and acute-phase with atherosclerosis in coronary and peripheral arteries and those arteries supplying the brain. Thromb Haemost. 1995;73:374–378 6) Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Plasma concentrations of C-reactive protein and risk of developing peripheral vascular disease. Circulation. 1998;97:425–428 7) Festa A, D'Agostino R Jr, Williams K, Karter AJ, Mayer-Davis EJ, Tracy RP, Haffner SM. The relation of body fat mass and distribution to markers of chronic inflammation. Int J Obes Relat Metab Disord. 2001 Oct;25(10):1407-15 8) Lemieux I, Pascot A, Prud'homme D, Almeras N, Bogaty P, Nadeau A, Bergeron J, Despres JP. Elevated C-reactive protein: another component of the atherothrombotic profile of abdominal obesity.Arterioscler Thromb Vasc Biol. 2001 Jun;21(6):961-7 9) Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol. 1999;19:972–978 10) Ridker PM. Novel risk factors and markers for coronary disease. Adv Intern Med. 2000; 45: 391–418 11) Rifai N, Tracy RP, Ridker PM. Clinical efficacy of an automated high-sensitivity C-reactive protein assay. Clin Chem. 1999; 45: 2136–2141 12) Ridker PM, Hennekens CH, Buring JE, et al. C reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342:836–843 13) Endothelin Antagonism and Interleukin-6 Inhibition Attenuate the Proatherogenic Effects of C-Reactive Protein; Subodh Verma, Shu-Hong Li, Mitesh V. Badiwala, Richard D. Weisel, Paul W.M. Fedak, Ren-Ke Li, Bikramjit Dhillon, and Donald A.G. Mickle References